Answers are grounded in this paper and cite their sources.
Neuroblastoma, a malignant embryonal tumor of early childhood, has the unique feature of regression after mild or even no chemotherapy in low risk patients. In contrast, most high-risk patients die of disease despite intensive multimodality treatments. It is, therefore, an ideal model tumor for establishing individualized therapies. For many years, neuroblastoma patients have undergone risk adapted treatment according to clinical and molecular characteristics of the patient and the tumor, respectively, at the time of diagnosis. Recently, other approaches such as treatment modifications based on response to treatment as well as targeted molecular therapies directed against distinct abnormal pathways are becoming increasingly important. Every approach must rely on prospectively evaluated treatment strategies.
No takes yet. Share an insight, caveat, or question.
Simon et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: